BASIC INFORMATION

Date & Time: March 19, 2026, 14:03:12 Indian Standard Time

Lecture Handout Prepared from the Teaching Session by: Dr. R. K. Mishra

SUMMARY

This lecture provides surgeons with a comprehensive framework for managing infertility associated with endometriosis, integrating principles of surgical intervention and Assisted Reproductive Technology (ART). It addresses the full spectrum of the disease, from endometriomas to deep infiltrating endometriosis (DIE). A central theme is the necessity of a patient-centered, multidisciplinary approach that balances fertility goals with the management of pain and the prevention of organ damage. Key discussions include the nuanced interpretation of ovarian reserve markers (AMH, AFC), the limitations of current clinical guidelines, and the critical importance of a thorough presurgical assessment to identify functionally debilitating symptoms beyond pain. The lecture advocates for a customized strategy, detailing the indications and evidence for both primary surgery and first-line ART, the principles of complete surgical excision for DIE, and the surgeon's vital role in preoperative counseling, postoperative management, and timely collaboration with fertility specialists to optimize patient outcomes.

KEY KNOWLEDGE POINTS

Endometriosis is a risk factor for infertility, not a definitive cause. The management of pain and infertility often requires conflicting strategies (hormonal suppression vs. active fertility treatment).
The management of deep infiltrating endometriosis (DIE) associated with infertility requires a customized approach, as current guidelines are inconclusive due to a lack of randomized controlled trials.
Indications for surgery in DIE extend beyond pain to include "red flag" symptoms like severe dyspareunia, bladder dysfunction (high post-void residual), severe bloating, and silent ureteral stenosis, which can cause irreversible organ damage.
Anti-Müllerian Hormone (AMH) reflects the functional ovarian reserve (growing follicles) and predicts IVF response; it is not a direct measure of absolute fertility or oocyte quality and is subject to significant variability.
Complete surgical excision of DIE by an experienced surgeon is a highly effective treatment that can restore natural fertility or improve subsequent ART success rates. Incomplete surgery offers no fertility benefit.
First-line ART is a powerful option, with studies showing cumulative live birth rates of approximately 65% for patients with DIE-associated infertility.
After two failed ART cycles in a patient with unoperated DIE, surgical intervention should be strongly considered.
A multidisciplinary approach, thorough patient counseling on risks and benefits, and comprehensive surgical reporting (r-ASRM, EFI) are essential for effective and medicolegally sound management.

INTRODUCTION

Endometriosis and infertility are intimately linked, presenting a significant clinical challenge for both surgeons and reproductive medicine specialists. While a diagnosis of endometriosis causes considerable patient anxiety, most affected individuals conceive without assistance. However, for a subset of patients, particularly those with endometriomas or deep infiltrating endometriosis (DIE), the disease significantly impairs fertility. The management paradigm is complex, as the primary treatment for pain—continuous hormonal suppression—is inherently contraceptive, while fertility treatments are incompatible with medical suppression. This dichotomy, coupled with a lack of definitive randomized trial evidence comparing surgery and ART, can lead to suboptimal outcomes, including iatrogenic damage to ovarian reserve or delayed fertility treatment. This session aims to bridge the knowledge gap by providing surgeons with essential principles of ART, ovarian physiology, and evidence-based surgical strategies to facilitate a collaborative, nuanced, and patient-centered approach to care.

LEARNING OBJECTIVES

To understand the relationship between endometriosis and infertility and the limitations of current clinical guidelines.
To correctly interpret ovarian reserve markers, particularly AMH and AFC, in the context of endometriosis.
To recognize the spectrum of clinical symptoms beyond pain that may serve as primary indications for surgical intervention in DIE.
To learn the principles of fertility preservation during surgical management and the importance of complete surgical excision.
To formulate a structured, multidisciplinary approach to patient counseling, shared decision-making, and postoperative management.

CORE CONTENT

1. The Endometriosis and Infertility Paradigm

The initial management of a patient diagnosed with endometriosis requires a "think infertility" mindset. A diagnosis of endometriosis is a risk factor, not a sentence of infertility. Management strategies must address the often-conflicting goals of pain relief and fertility enhancement.

Medical Treatment: Continuous hormonal therapy to induce amenorrhea is the standard for pain management but is contraceptive.
Surgical Treatment: Surgery is complementary and may be indicated for pain, infertility, or both.
Fertility Treatment: ART and other fertility-enhancing strategies are incompatible with hormonal suppression.

2. Understanding Ovarian Reserve and Folliculogenesis

Misinterpretation of ovarian reserve markers is a common pitfall.

2.1. The "Cherry Tree" Model of Folliculogenesis

This analogy helps clarify the process for surgeons:

Primordial Follicles (the "Buds"): This is the true, finite ovarian reserve established at birth. They are dormant and cannot be visualized or measured by hormones.
Growing Follicles (the "Blossoms" and "Green Cherries"): A continuous stream of follicles recruited from the primordial pool. The antral follicles (2-8 mm) within this group are visible on ultrasound and constitute the Antral Follicle Count (AFC).
Dominant Follicle (the mature "Cherry"): Each cycle, one follicle is selected to ovulate.

2.2. The Role of Anti-Müllerian Hormone (AMH)

AMH is produced by the granulosa cells of growing follicles only, not primordial follicles.
It is a marker of the functional ovarian reserve (the pool available for stimulation), not the total lifetime reserve.
Its primary clinical utility in ART is to predict ovarian response to gonadotropin stimulation (risk of poor vs. hyper-response) and to guide dosing.
Crucially, AMH is not a direct marker of fertility or oocyte quality. It can fluctuate significantly due to lab assays and physiological factors (e.g., it is suppressed by hormonal contraceptives).

3. Management of Endometriomas and Ovarian Reserve

Preoperative Assessment: A formal assessment of ovarian reserve (AMH and AFC) is mandatory before any surgery for endometriomas, especially if bilateral.
Iatrogenic Harm: The primary risk of endometrioma surgery is inadvertent removal of healthy ovarian cortex, which contains the primordial follicle pool.
Postoperative AMH: Do not test AMH immediately after surgery. Wait at least 6-12 months. Surgery causes a temporary decrease in AMH due to its effect on growing follicles. If the primordial stock is preserved, AMH levels may recover.

4. Management of Deep Infiltrating Endometriosis (DIE) and Infertility

The choice between primary surgery and first-line ART is a central dilemma, as high-level evidence from RCTs is lacking.

4.1. The Case for First-Line ART

Robust prospective cohort studies show high cumulative live birth rates (approx. 65-73%) with first-line IVF for DIE-associated infertility. This makes ART a powerful and valid primary strategy.

4.2. The Case for Primary Surgery

Fertility Outcomes: Complete surgical excision of DIE can lead to high rates of spontaneous pregnancy (up to 74% in infertile cohorts) and improved outcomes in subsequent ART. Incomplete surgery (e.g., adhesiolysis only) provides no fertility benefit.
Indications Beyond Pain: The decision for surgery should not be based on pain alone. "Red flag" symptoms that may warrant primary surgery include:
- Deep Dyspareunia: Indicates significant rectovaginal disease.
- Bladder Dysfunction: Symptoms like dysuria or needing to push to void, especially with a high post-void residual volume, suggest nerve compromise and risk of irreversible bladder atony.
- Severe Bloating: May indicate significant bowel involvement and risk of obstruction, especially during ovarian stimulation.
- Silent Ureteral Stenosis: Parametrial endometriosis can cause asymptomatic hydronephrosis and silent loss of a kidney. This is a critical finding mandating surgical consideration.
Surgery after ART Failure: For patients who choose first-line ART, surgery should be strongly considered after two failed cycles, as the cumulative success of ART diminishes significantly thereafter.

SURGICAL PEARLS

Comprehensive Assessment: Always perform a thorough clinical assessment and obtain high-quality imaging (e.g., MRI) before deciding on a management plan for DIE to identify silent but severe pathology.
Interpret AMH Critically: Never give a definitive prognosis based on a single low AMH value. It is a tool to predict IVF response, not absolute fertility.
Avoid Incomplete Surgery: For DIE, performing adhesiolysis without resecting the deep nodules is futile for improving fertility and exposes the patient to unnecessary risk.
Conservative Ovarian Surgery: When operating for DIE with co-existing endometriomas, consider conservative techniques like ablation or drainage of the endometrioma to preserve ovarian reserve, especially if ART is planned.
Low AMH and DIE: In a patient with low AMH, where ART outcomes may be poor, surgery to restore anatomy and enable natural conception can be a very logical strategy.
Surgical Report Documentation: Systematically include r-ASRM and EFI scores in your operative reports to provide objective data for future fertility management.

COMPLICATIONS AND THEIR MANAGEMENT

Intraoperative:
- The primary iatrogenic risk of endometrioma surgery is the removal of healthy ovarian cortex, reducing the primordial follicle pool.
- In DIE surgery, risks include injury to the ureters, bowel, major vessels, and pelvic nerves, requiring immediate recognition and repair.
Early Postoperative:
- The severe complication rate (Clavien-Dindo ≥ Grade 3) for colorectal DIE surgery is approximately 3-5%.
- Major complications include rectovaginal fistula and anastomotic leakage. While serious, studies show subsequent pregnancy is still possible.
Late Postoperative/Disease Progression:
- Bladder Atony: Progressive loss of bladder function from neurological compromise due to parametrial DIE. Requires surgical decompression, but recovery is not guaranteed if delayed.
- Loss of Renal Function: Chronic, silent ureteral obstruction from endometriosis can lead to a non-functioning kidney, a preventable catastrophe.
- Recurrence: Failure to prescribe postoperative hormonal suppression until pregnancy is desired can lead to rapid recurrence of disease and pain.

MEDICOLEGAL AND PATIENT SELECTION CONSIDERATIONS

Informed Consent: The potential impact of surgery on ovarian reserve and the risks of major complications must be a central part of the informed consent process.
Shared Decision-Making: The choice between primary surgery and first-line ART must be individualized. Clinicians must present all available data on success rates and risks, allowing the patient to make an informed choice based on her priorities.
Multidisciplinary Team (MDT): All complex cases of infertile women with DIE should be discussed in an MDT meeting involving DIE surgeons, ART specialists, and radiologists to ensure a consensus-based management plan.
Avoiding Misinformation: Do not tell a patient she is "cured" by surgery. Emphasize that endometriosis is a chronic disease requiring long-term management. Do not provide a definitive fertility prognosis based solely on an AMH test.

SUMMARY AND TAKE-HOME MESSAGES

Surgeons must adopt a proactive, "think infertility" approach from the moment an endometriosis diagnosis is made, balancing pain management with fertility preservation.
The decision between primary surgery and ART for DIE-associated infertility must be customized, moving beyond the simplistic indication of "pain" to include a full assessment of organ function and patient priorities.
Complete surgical excision of DIE is a valid and highly effective treatment for restoring fertility, while AMH is a useful but limited tool that must be interpreted with caution.
Collaboration is essential. A multidisciplinary approach involving surgeons and fertility specialists is the cornerstone of providing safe, effective, and comprehensive care for this complex patient population.

MULTIPLE CHOICE QUESTIONS (MCQs)

Anti-Müllerian Hormone (AMH) is a direct measure of:

a) The total primordial follicle pool.

b) The functional ovarian reserve of growing follicles.

c) Oocyte quality and aneuploidy rate.

d) The presence of deep infiltrating endometriosis.
According to the "Cherry Tree" model, the true, finite ovarian reserve corresponds to:

a) The mature cherries.

b) The cherry blossoms.

c) The buds on the tree.

d) The cherry pit.
A surgeon performs a cystectomy for bilateral endometriomas. When is the most appropriate time to re-evaluate the patient's AMH level postoperatively?

a) At the 1-week follow-up.

b) At the 6-week postoperative check.

c) Between 3 and 6 months after surgery.

d) At least 12 months after surgery.
Which symptom was highlighted as a "red flag" for potential irreversible organ damage in a patient with deep endometriosis?

a) Mild dysmenorrhea.

b) Premenstrual spotting.

c) The need to push to void the bladder.

d) Fatigue.
Studies on first-line IVF for deep endometriosis-associated infertility show a cumulative live birth rate of approximately:

a) 35%

b) 45%

c) 65%

d) 85%
After how many failed ART cycles should surgical intervention be strongly considered for a patient with unoperated deep infiltrating endometriosis?

a) One cycle.

b) Two cycles.

c) Four cycles.

d) After the patient requests it, regardless of cycle number.
Which of the following offers no fertility benefit in patients with deep infiltrating endometriosis?

a) Shaving technique for rectal nodules.

b) Discoid resection of a bowel nodule.

c) Laparoscopic adhesiolysis without excision of deep nodules.

d) Segmental colorectal resection.
What is a critical piece of information a surgeon should include in the operative report for a patient with infertility?

a) The brand of energy device used.

b) The r-ASRM and/or EFI score.

c) The total volume of irrigation fluid used.

d) The names of the nursing staff in the room.
Silent loss of a kidney can occur in endometriosis due to:

a) Renal artery thrombosis.

b) Chronic, asymptomatic ureteral stenosis from parametrial involvement.

c) Autoimmune attack on the kidney.

d) Ovarian vein thrombosis extending to the renal vein.
What is the recommended management for a patient diagnosed with endometriosis who is not currently trying to conceive?

a) Advise immediate pregnancy to "cure" the disease.

b) Recommend prophylactic oophorectomy.

c) Obtain amenorrhea with medical treatment and counsel on future fertility planning.

d) Perform immediate surgery regardless of symptoms.
Which statement about AMH is most accurate?

a) A single low AMH value definitively means a patient is infertile.

b) Hormonal contraceptive use significantly increases AMH levels.

c) AMH can be low even in patients with only superficial endometriosis.

d) AMH is a stable hormone with minimal laboratory-to-laboratory variability.
The primary iatrogenic risk of endometrioma surgery on fertility is:

a) Increased risk of postoperative infection.

b) Damage to the fallopian tube.

c) Removal of healthy ovarian cortex, reducing the follicular pool.

d) Creation of dense pelvic adhesions.
For a patient with DIE, severe bloating can be a concerning symptom because it may indicate:

a) An impending risk of bowel obstruction, especially after ovarian stimulation.

b) The presence of adenomyosis.

c) A high likelihood of ovarian cancer.

d) Liver metastasis.
What is the approximate severe complication rate (Clavien-Dindo ≥ Grade 3) for surgery involving colorectal endometriosis?

a) <1%

b) 3-5%

c) 10-15%

d) >20%
In a patient with a low AMH and symptomatic DIE, a reasonable strategy is to:

a) Avoid surgery at all costs.

b) Proceed directly to oocyte donation.

c) Consider surgery to alleviate symptoms and potentially enable natural conception.

d) Administer 6 months of GnRH agonists before any other treatment.
A major reason for slow enrollment in RCTs comparing surgery and ART for DIE is:

a) Lack of funding for such trials.

b) Patients often have a strong preference for one treatment, making randomization difficult.

c) The surgical techniques are considered experimental.

d) ART specialists refuse to participate in the trials.
Which anatomical location of DIE is most associated with bladder atony and ureteral stenosis?

a) The diaphragm.

b) The uterosacral ligaments.

c) The parametrium.

d) The appendix.
The primary reason medical treatment for endometriosis pain is incompatible with fertility treatment is that it is:

a) Too expensive for most patients.

b) Associated with severe side effects.

c) Contraceptive by nature.

d) Ineffective at controlling pain.
A high post-void residual volume (e.g., 300 mL) in a woman with DIE and infertility should prompt:

a) Immediate initiation of the planned IVF cycle.

b) Strong consideration for surgical intervention to decompress nerves.

c) A prescription for a diuretic.

d) Reassurance and observation for 6 months.
What is the central message of this lecture for surgeons managing endometriosis?

a) Surgery is always superior to ART for infertility.

b) AMH is an unreliable test that should be abandoned.

c) All women with endometriosis require IVF.

d) Adopt a critical, multidisciplinary, and customized approach to preserve fertility and prevent iatrogenic harm.

Answer Key: 1(b), 2(c), 3(d), 4(c), 5(c), 6(b), 7(c), 8(b), 9(b), 10(c), 11(c), 12(c), 13(a), 14(b), 15(c), 16(b), 17(c), 18(c), 19(b), 20(d)

MOTIVATIONAL MESSAGE FROM DR. R. K. MISHRA

The path to mastery in surgery is paved not with the stones of ego, but with the bricks of relentless inquiry and humble reflection. Question every assumption, learn from every outcome, and let the well-being of your patient be the unwavering compass that guides every decision.

I wish you all unwavering dedication and profound insight in your surgical careers.